GLS — Glenmark Life Sciences Cashflow Statement
0.000.00%
Last trade - 00:00- IN₹103.82bn
- IN₹100.08bn
- IN₹22.83bn
- 97
- 27
- 68
- 74
Annual cashflow statement for Glenmark Life Sciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | PRESS |
| Standards: | IAS | IAS | IAS | IAS | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 4,211 | 4,709 | 5,649 | 6,286 | 6,313 |
| Depreciation | |||||
| Non-Cash Items | 277 | 1,003 | 399 | 89.9 | 378 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2,832 | -2,166 | -451 | -3,663 | -3,091 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 1,950 | 3,881 | 5,976 | 3,134 | 4,135 |
| Capital Expenditures | -512 | -680 | -1,322 | -1,702 | -1,290 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 6.48 | -7.41 | 99.4 | 161 | 125 |
| Sale of Fixed Assets | |||||
| Change in Net Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -505 | -687 | -1,222 | -1,541 | -1,165 |
| Financing Cash Flow Items | — | — | -0.72 | -0.32 | -15.5 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -1,366 | -2,138 | -788 | -3,876 | -2,794 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 79.4 | 1,056 | 3,966 | -2,283 | 176 |